Fluvirin: PowderJect's Best Shot

Expanding the market for flu vaccine Fluvirin is PowderJect's near-term priority, given that the product accounts for 65% of sales. But the drug-delivery-turned-vaccines player is also trying to realize value from its needle-free injection technology, by way of second-generation vaccines.

The lines forming outside Asda supermarkets across the UK early last November 9 weren't just for last-minute tea and toast. British consumers were spending their Saturday morning queuing up—some reports suggest even before stores were opened—to get stuck with PowderMed Ltd.'s Fluvirin influenza vaccine, at a cost of £12 ($19) each.

In fact, 35,000 Brits received Fluvirin at Asda stores on October 12. The success of the first stage of this...

More from Global Vision

More from In Vivo